IR813-Induced Photothermal Therapy: Leveraging Immunogenic Cell Death for Cancer Treatment DOI Creative Commons
Guangwei Jiang, Rong Huang, Min Qian

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 166 - 166

Published: Jan. 26, 2025

Background: Photothermal therapy has the potential to enhance precision and safety of oncological treatments. However, applicable photothermal agents associated with its activated immunogenic cell death remain exploiting. Methods: This study evaluates effectiveness IR813, a agent, combined near-infrared (NIR) light for cancer treatment. In vitro, 4T1 cells were treated IR813 (5 μg/mL) exposed NIR irradiation (1 W/cm2) 5 min. vivo, after tumor-bearing mice administered mg/kg) 10 min, tumor volume, survival immune activation evaluated. Results: significantly increased cytotoxicity following irradiation, resulting in release damage-associated molecular patterns death. Specifically, viability was reduced 5% compared control group. irradiating accumulation at site had mediate substantial suppression, improved mouse survival, metastasis, minimal adverse reactions. Furthermore, responses stimulated by IR813-induced evidenced mature dendritic cytotoxic T lymphocyte counts decrease regulatory spleen, tumor, lymph nodes. Conclusions: These findings suggest that is promising approach enhancing immunotherapy, directly inhibiting tumors while boosting systemic anti-cancer immunity.

Language: Английский

Platelet membrane fusion liposome loaded with type I AIE photosensitizer to induce chemoresistance cancer pyroptosis and immunogenic cell death for enhancing cancer immunotherapy DOI
Hao Chen, Xi Luo, Qinghua Huang

et al.

Chemical Engineering Journal, Journal Year: 2023, Volume and Issue: 476, P. 146276 - 146276

Published: Oct. 11, 2023

Language: Английский

Citations

26
Biomaterials Elicit Pyroptosis Enhancing Cancer Immunotherapy DOI

Meng‐Jie Zhang,

Yuanyuan Wang,

Lin‐Lin Han

et al.

Advanced Functional Materials, Journal Year: 2023, Volume and Issue: 34(7)

Published: Nov. 5, 2023

Abstract Cancer immunotherapy has the potential to revolutionize treatment of malignant tumors, but its effectiveness is limited by low immune response rate and immune‐related adverse events. Pyroptosis, as an inflammatory programmed cell death type, triggers strong acute antitumor immunity, converting “cold” tumors “hot”. Particularly, biomaterials loading pyroptosis inducers targeting tumor microenvironment engineer pyroptosis, have achieved great progress in recent years. Herein, design strategy, mechanism pathway, role induce cancer are comprehensively reviewed. The present review focuses on application biomaterials‐induced immunotherapy, including nanogel, polymer prodrug, nanovesicle, mesoporous material. Additionally, synthesis a series stimuli‐responsive nanoplatforms, glutathione‐responsive, pH‐responsive, reactive oxygen species‐responsive, enzyme‐mimicking catalytic performance, described. Meanwhile, it augments multiple processes uptake, antigen presentation, T‐cell activation, expansion. Finally, perspectives pyroptosis‐mediated inflammation break through vascular basement membrane barrier achieving efficient volcanic penetration discussed. Artificial intelligence, multi‐omics analysis, anthropogenic animal models organoids presented, aiming provide guidance assistance for constructing effective controllable pyroptosis‐engineered improving immunotherapy.

Language: Английский

Citations

25
Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis DOI Creative Commons
Lin Wu, Yingzi Zhang, Yan Yang

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(30)

Published: Aug. 16, 2023

The majority of patients with human epidermal growth factor receptor 2 (Her2)-positive gastric cancer develop refractory to Her2-targeted therapy, where upregulation immune checkpoints plays an essential role. Herein, a recombinant fully IgG1 bispecific antibody IBI315 targeting both PD-1 and Her2 is developed its antitumor efficacy as well the underlying mechanism investigated. crosslinks physical interaction between Her2-positive tumor cells PD-1-positive T cells, resulting in significantly enhanced effects compared each parent or their combination, vitro vivo mouse models reconstituted using patient-derived xenografts organoids. Moreover, treatment also induces recruitment activation tumors. Mechanistically, triggers gasdermin B (GSDMB)-mediated pyroptosis leading recruiments cells. activated secret IFNγ, enhancing GSDMB expression establishing positive feedback loop cell killing. Notably, found be elevated providing rationale for IBI315's efficacy. supported here promising antibody-based immunotherapy approach preclinical studies, broadening therapeutic landscape this patient population.

Language: Английский

Citations

24
Cell-mediated nanoparticle delivery systems: towards precision nanomedicine DOI Creative Commons
Ruoyu Cheng, Shiqi Wang

Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: 14(11), P. 3032 - 3054

Published: April 13, 2024

Cell-mediated nanoparticle delivery systems (CMNDDs) utilize cells as carriers to deliver the drug-loaded nanoparticles. Unlike traditional drug approaches, CMNDDs take advantages of cell characteristics, such homing capabilities stem cells, inflammatory chemotaxis neutrophils, prolonged blood circulation red and internalization macrophages. Subsequently, can easily prolong circulation, cross biological barriers, blood-brain barrier bone marrow-blood barrier, rapidly arrive at diseased areas. Such advantageous properties make promising candidates for precision targeting. In this review, we summarize recent advances in fabrication biomedical applications. Specifically, ligand-receptor interactions, non-covalent covalent are commonly applied constructing vitro. By hitchhiking macrophages, monocytes, platelets, nanoparticles be internalized or attached construct vivo. Then highlight application treating different diseases, cancer, central nervous system disorders, lung cardiovascular with a brief discussion about challenges future perspectives end.

Language: Английский

Citations

12
Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives DOI
Muhammad Umar Farooq, Charles H. Lawrie, Nan‐Nan Deng

et al.

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 486, P. 150356 - 150356

Published: March 14, 2024

Language: Английский

Citations

9
Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy DOI Creative Commons
Qing Tong, Kexin Li,

Fanwei Huang

et al.

Materials Today Bio, Journal Year: 2023, Volume and Issue: 23, P. 100845 - 100845

Published: Oct. 27, 2023

Combination immunotherapy of cancer vaccines with immune checkpoint inhibitors (ICIs) represents a promising therapeutic strategy for immunosuppressed and cold tumors. However, this still faces challenges, including the limited efficacy immune-related adverse events associated systematic delivery ICIs. Herein, we demonstrate antitumor response induced by outer membrane vesicle from Akkermansia muciniphila (Akk-OMV), which exhibites favorable safety profile, highlighting potential application as natural biocompatible self-adjuvanting vesicle. Utilizing tumor cell-derived exosome an antigen source Akk-OMV adjuvant, construct vaccine formulation extracellular vesicles hybrid lipid nanovesicles (Lipo@HEV) enhanced prophylactic vaccination promoting dendritic cell (DC) maturation in lymph node activating cytotoxic T (CTL) response. The Lipo@HEV is further loaded plasmid to enable gene therapy-mediated PD-L1 blockade upon peritumoral injection. Meanwhile, it penetrates into initiate DC CTL activation, synergistically inhibiting established tumor. fabrication plasmid-loaded reveals therapy-guided vesicle-based system synergistic strategy.

Language: Английский

Citations

19
Apoptosis‐Sensitizing Tumor Nanomedicine by Regulating Pyroptosis‐Associated Inflammatory Cell Death DOI

Fangxue Du,

Hongxin Zhao,

Yangmeihui Song

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(44)

Published: May 25, 2024

Abstract The vigorous development of cancer nanomedicine has revolutionized traditional oncology medicine, but it is also limited by the continuous mutation cunning cells, leading to apoptosis insensitivity and therapeutic disappointment. Inflammatory‐regulated cell death (RCD), especially pyroptosis‐related death, demonstrates huge potential for sensitization due its unique biochemical characteristics. aim this research present a thorough synopsis current knowledge on pyroptosis‐associated inflammatory including pyroptosis, cuproptosis, PANoptosis, synergistic function in nano therapy. Paradigm studies death‐mediated apoptosis‐sensitizing tumor nanotherapeutics are introduced detail, coordination mechanisms based nanomaterials discussed. In addition, multi‐angle analysis future prospects pyroptosis‐sensitized various emphasized further expand application scope RCD. It believed that emerging auxiliary treatments RCD will greatly promote progress nanomedicine.

Language: Английский

Citations

7
Multi‐Enzyme Nanoparticles as Efficient Pyroptosis and Immunogenic Cell Death Inducers for Cancer Immunotherapy DOI Creative Commons

Hekai Yang,

Guangzhao Xu, Fahui Li

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(44)

Published: Oct. 9, 2024

Abstract Immunotherapy represents a widely employed modality in clinical oncology, leveraging the activation of human immune system to target and eradicate cancer cells tumor tissues via endogenous mechanisms. However, its efficacy remains constrained by inadequate responses within “cold” microenvironment (TME). In this study, multifunctional nanoscale pyroptosis inducer with cascade enzymatic activity (IMZF), comprising superoxide dismutase (SOD), catalase (CAT), peroxidase (POD), glutathione oxidase (GSHO x ), is dissociated acidic glutathione‐rich TME. The vigorous not only generates oxygen (O 2 ) alleviate hypoxia promote M2 M1 macrophage polarization but also yields reactive species (ROS) depletes (GSH) Functioning as an immunogenic cell death (ICD) activator inducer, IMZF synergistically triggers dendritic maturation inflammatory lymphocyte infiltration ICD‐associated pyroptosis, thereby reversing suppression TMEs. Consequently, it exerts inhibitory effects on both primary distal tumors. This platform‐based offers intelligent strategy for effectively overcoming tumors, providing promising avenue advanced immunotherapeutic interventions.

Language: Английский

Citations

7
Advanced hitchhiking nanomaterials for biomedical applications DOI Creative Commons
Ying Wang, Shao‐Kai Sun, Yang Liu

et al.

Theranostics, Journal Year: 2023, Volume and Issue: 13(14), P. 4781 - 4801

Published: Jan. 1, 2023

Hitchhiking, a recently developed bio-inspired cargo delivery system, has been harnessed for diverse applications.By leveraging the interactions between nanoparticles and circulatory cells or proteins, hitchhiking enables efficient navigation through vasculature while evading immune system clearance.Moreover, it allows targeted of nutrients to tissues, surveillance pathogen elimination.Various synthetic nanomaterials have facilitate with proteins.By combining advantages demonstrate several over conventional vectors, including enhanced stability optimized therapeutic efficacy.This review provides an overview general strategies hitchhiking, choices recent advances biomedical applications.

Language: Английский

Citations

15
Neutrophil‐Mediated Tumor‐Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy DOI Creative Commons
L L Liu,

Wenjie Xin,

Qiang Li

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(29)

Published: Aug. 10, 2023

Abstract Oncolytic bacteria are the most promising tumor target vector. Questions also remain regarding finding a balance between therapeutic efficacy and safety of oncolytic bacteria. The critical measure how this is maintained improvement in colonization. Attenuated Salmonella typhimurium (VNP20009) as only strain to be evaluated clinical trial potential bacterium. A delivery system with controlled release VNP after being loaded into neutrophils, which significantly increases tumor‐targeting enhances its melanoma lung metastasis model constructed. To improve synergistic effect, PD1 nanobody applied (NE(PD1nb)). NE(PD1nb) activate dendritic cells (DCs) differentiation stimulate M1‐like macrophages, induce CD4 + T‐cells maturity cytotoxic CD8 activation through DCs antigen presentation.

Language: Английский

Citations

13